The Economic Times

Vitruvias Therapeutics thyroid tablet recall gets FDAs highest-risk rating - heres what to check and what patients need to know

A thyroid medicine recall has received the FDAs highest-risk classification after testing found one lot of Thyroid Tablets, USP 30 mg could be stronger than intended. Heres what consumers need to know about the recalled lot, potential risks, affected tablets and what the FDA advises.